New York State Teachers Retirement System cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 0.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 71,203 shares of the biotechnology company’s stock after selling 200 shares during the period. New York State Teachers Retirement System’s holdings in United Therapeutics were worth $7,754,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of UTHR. Globeflex Capital L P bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $192,000. Advisor Partners LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $201,000. First Citizens Bank & Trust Co. bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $217,000. Unison Advisors LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $224,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $229,000. 97.61% of the stock is currently owned by hedge funds and other institutional investors.
UTHR has been the topic of a number of research analyst reports. Cowen set a $106.00 target price on shares of United Therapeutics and gave the company a “hold” rating in a report on Wednesday, October 31st. Credit Suisse Group upped their target price on shares of United Therapeutics from $103.00 to $105.00 and gave the company a “sell” rating in a report on Monday, November 19th. BidaskClub cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 31st. Oppenheimer set a $160.00 target price on shares of United Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 20th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a report on Thursday, November 1st. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $134.00.
United Therapeutics stock opened at $116.95 on Wednesday. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of 8.33, a P/E/G ratio of 44.01 and a beta of 1.05. The company has a current ratio of 4.32, a quick ratio of 4.05 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a twelve month low of $100.06 and a twelve month high of $139.54.
In other United Therapeutics news, CEO Martine A. Rothblatt sold 7,054 shares of the stock in a transaction dated Tuesday, January 8th. The shares were sold at an average price of $113.16, for a total value of $798,230.64. Following the transaction, the chief executive officer now directly owns 7,195 shares of the company’s stock, valued at approximately $814,186.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christopher Causey sold 580 shares of the stock in a transaction dated Saturday, August 3rd. The shares were sold at an average price of $127.48, for a total transaction of $73,938.40. Following the completion of the transaction, the director now directly owns 1,605 shares in the company, valued at $204,605.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 99,737 shares of company stock worth $11,395,752. Insiders own 8.20% of the company’s stock.
WARNING: “New York State Teachers Retirement System Has $7.75 Million Holdings in United Therapeutics Co. (UTHR)” was published by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://theenterpriseleader.com/2019/02/06/new-york-state-teachers-retirement-system-has-7-75-million-holdings-in-united-therapeutics-co-uthr.html.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Story: Understanding each part of a balance sheet
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.